Worldwide Clinical Trials appoints Evelyn Graham

To lead sales, marketing and business development for late-stage business

Worldwide Clinical Trials, a US-based global contract research organisation, has appointed Evelyn Graham as executive vice president, Global Business Development.

With more than 20 years of drug development experience, Graham will lead sales, marketing and business development strategies for the late stage business.

Graham was formerly chief executive of TorreyPines Therapeutics and led the company’s merger with Raptor Pharmaceuticals in September 2009.

You may also like

Research & Development
Octane Biotech and Currus Biologics automate CUR-001 CAR T-cell manufacturing on the Cocoon platform

Octane Biotech and Currus Biologics automate CUR-001 CAR T-cell manufacturing on the Cocoon platform

Closed, automated process will support Currus’ Phase I trial in mesothelin-positive solid tumours ... with first dosing expected in early 2027
Research & Development
Atelerix and Frontier Space partner to enable biological sample preservation for space missions

Atelerix and Frontier Space partner to enable biological sample preservation for space missions

Partnership creates a pathway to commercial adoption of Atelerix’s patented preservation technology in space biotechnology, with launch opportunities targeted for 2027
Manufacturing
Viewlinc Cloud Suite supports life science innovation from laboratory to regulated operations

Viewlinc Cloud Suite supports life science innovation from laboratory to regulated operations

Cloud-based environmental monitoring helps life science organisations establish professional-quality monitoring from day one and scale as requirements evolve
Research & Development
University of Sussex research reveals how leukaemia cells evade treatment

University of Sussex research reveals how leukaemia cells evade treatment

Computer modelling and patient samples reveal alternative survival signalling in CLL, potentially enabling earlier treatment choices and more personalised care
Drug Delivery
Promega UK launches Lumit insulin immunoassay

Promega UK launches Lumit insulin immunoassay

Wash-free assay enables rapid measurement of insulin secretion for metabolic disease drug discovery
Manufacturing
Lonza launches enhanced DNA-to-IND offering, enabling IND readiness in as Little as six months for more complex biologics

Lonza launches enhanced DNA-to-IND offering, enabling IND readiness in as Little as six months for more complex biologics

Lonza, the world’s leading contract development and manufacturing organisation (CDMO), announced today the expansion of its accelerated DNA–to-Investigational New Drug (IND) offering to support non-mAb biologics, including bispecific antibodies, Fc-fusion proteins and high-concentration drug product formulations
Research & Development
Amgen and AstraZeneca report positive Phase III results for Tezspire in EoE

Amgen and AstraZeneca report positive Phase III results for Tezspire in EoE

Tezspire improved swallowing symptoms and reduced oesophageal inflammation in patients with eosinophilic oesophagitis, with benefits sustained through 52 weeks, supporting its potential as a third indication
Subscribe now